NHS
Sticking the boot in
April 18, 2016Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair
A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …
UK’s genomics and personalised medicine expertise showcased at major international gathering
April 8, 2016Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader
The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …
Janssen-Cilag’s HIV treatment gets NHS backing
March 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial
Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV. The company said following the …
Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Top 10 medicines issued in England by prescription cost in 2014-15
March 2, 2016Research and Development, Sales and Marketing Cost, Humira, NHS, prescription
AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision
February 8, 2016Medical Communications, Sales and Marketing Jeremy Hunt, NHS
UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …
NICE recommends six drugs in final guidance
January 27, 2016Research and Development, Sales and Marketing NHS, NICE
NICE has published final recommendations approving drug treatments for ovarian cancer, prostate cancer, multiple myeloma, gastric cancer and idiopathic pulmonary …
UK Pfizer boss criticised for NHS conflict of interest
January 21, 2016Erik Nordkamp, Keep Our NHS Public, King's College Hospitals NHS Trsut, NHS, Pfizer, conflict of interest, privitisation
Anti-privatisation campaigners have called on a London NHS hospital trust to revoke its decision to appoint the head of Pfizer …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
NICE says no to NHS funding for Kadcyla
December 16, 2015Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer
NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
NHS England reinstates treatments to Cancer Drugs Fund
November 4, 2015Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NHS England
Five treatments in seven indications have been reinstated to Cancer Drugs Fund, as a result of negotiations between pharma companies …
NHS set for digital health tech review
October 30, 2015Medical Communications Jeremy Hunt, NHS, Robert Wachter, digital health, health secretary
Health secretary Jeremy Hunt says turning the NHS into a “patient-powered, technologically advanced health service” is “one of the most …
Otsuka kidney drug earns first NICE nod
October 28, 2015Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan
NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
OPINION: ‘More work remains if biosimilars are to fulfil their potential’
October 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents
Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
